Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: Diagnostic validity and significant reduction of cfDNA after surgical resection

Annals of Surgical Treatment and Research

Volumn 86, Issue 3, 2014, Pages 136-142

  Kim, Kyongchol ^a   Shin, Dong Gue ^b   Park, Min Koo ^c   Baik, Seung Hyuk ^d   Kim, Tae Hee ^e   Kim, Sanghee ^f   Lee, Sae Young ^g  

^a CHA University   (South Korea)

^b Seoul Medical Center   (South Korea)

^c TCM Epigenetics and Genomics Lab   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Seoul Metropolitan Dong Bu Hospital   (South Korea)

^f Yonsei University   (South Korea)

^g Mizmedi Hospital   (South Korea)

Author keywords

Biological biomarker; Circulating free DNA; Gastric neoplasms

Indexed keywords

EID: 84905036017     PISSN: 22886575     EISSN: 22886796     Source Type: Journal    
DOI: 10.4174/astr.2014.86.3.136     Document Type: Article

References (26)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide [Internet]. Lyon: International Agency for Research on Cancer; c2010 [cited 2013 Aug 30]. Available from: http://www.iarc.fr/en/media-centre/iarcnews/2010/globocan2008.php.
2. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: A global overview. Int J Cancer 2009; 125: 666-73.
3. Wang J, Yu JC, Kang WM, Ma ZQ. Treatment strategy for early gastric cancer. Surg Oncol 2012; 21: 119-23.
4. Strong VE, D'Amico TA, Kleinberg L, Ajani J. Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Canc Netw 2013; 11: 60-6.
5. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426-37.
6. Anker P, Stroun M. Circulating DNA in plasma or serum. Medicina (B Aires) 2000; 60(5 Pt 2): 699-702.
7. Cui M, Fan M, Jing R, Wang H, Qin J, Sheng H, et al. Cell-Free circulating DNA: A new biomarker for the acute coronary syndrome. Cardiology 2013; 124: 76-84.
8. De Mattos-Arruda L, Olmos D, Tabernero J. Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. Future Oncol 2011; 7: 1385-97.
9. Mead R, Duku M, Bhandari P, Cree IA. Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer 2011; 105: 239-45.
10. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007; 635: 105-17.
11. Lecomte T, Berger A, Zinzindohoue F, Micard S, Landi B, Blons H, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 2002; 100: 542-8.
12. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
13. Xue X, Teare MD, Holen I, Zhu YM, Woll PJ. Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clin Chim Acta 2009; 404: 100-4.
14. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat 2013; 45: 1-14.
15. Park SM, Lim MK, Jung KW, Shin SA, Yoo KY, Yun YH, et al. Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. J Clin Oncol 2007; 25: 4835-43.
16. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, et al. Plasma cell-free DNA in ovarian cancer: An independent prognostic biomarker. Cancer 2010; 116: 1918-25.
17. Morgan SR, Whiteley J, Donald E, Smith J, Eisenberg MT, Kallam E, et al. Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples. Clin Med Insights Pathol 2012; 5: 15-22.
18. Tomochika S, Iizuka N, Watanabe Y, Tsutsui M, Takeda S, Yoshino S, et al. Increased serum cell-free DNA levels in relation to inflammation are predictive of distant metastasis of esophageal squamous cell carcinoma. Exp Ther Med 2010; 1: 89-92.
19. Agostini M, Enzo MV, Bedin C, Belardinelli V, Goldin E, Del Bianco P, et al. Circulating cell-free DNA: A promising marker of regional lymphonode metastasis in breast cancer patients. Cancer Biomark 2012; 11: 89-98.
20. Hashad D, Sorour A, Ghazal A, Talaat I. Free circulating tumor DNA as a diagnostic marker for breast cancer. J Clin Lab Anal 2012; 26: 467-72.
21. Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: A systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer 2014; 17: 26-33.
22. Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 2010; 17: R245-62.
23. Levy M, Benesova L, Lipska L, Belsanova B, Minarikova P, Veprekova G, et al. Utility of cell-free tumour DNA for post-surgical follow-up of colorectal cancer patients. Anticancer Res 2012; 32: 1621-6.
24. Agostini M, Pucciarelli S, Enzo MV, Del Bianco P, Briarava M, Bedin C, et al. Circulating cell-free DNA: A promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann Surg Oncol 2011; 18: 2461-8.
25. Lee YJ, Yoon KA, Han JY, Kim HT, Yun T, Lee GK, et al. Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Clin Cancer Res 2011; 17: 5179-87.
26. Umetani N, Hiramatsu S, Hoon DS. Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. Ann N Y Acad Sci 2006; 1075: 299-307.